The role of imaging in the clinical development of antiangiogenic agents.

摘要: Early clinical development of novel antiangiogenesis agents is hampered by the fact that classic response end points are unlikely to be relevant and there a lack validated surrogate markers efficacy. Toxicity-based decisions for dose setting tumor size measurements standard imaging probably not applicable. Because these modify multitude biologic processes may cause early measurable effects, great interest in developing tests sensitive changes tissue function. This article discusses such "functional" attempts address questions being asked departments oncologists pharmaceutical companies.